Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells $2,557,260.92 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 90,941 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $28.12, for a total value of $2,557,260.92. Following the completion of the transaction, the director directly owned 1,180,060 shares in the company, valued at $33,183,287.20. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, October 24th, Ra Capital Management, L.P. sold 53,345 shares of Vor Biopharma stock. The stock was sold at an average price of $28.01, for a total value of $1,494,193.45.
• On Thursday, October 23rd, Ra Capital Management, L.P. sold 76,880 shares of Vor Biopharma stock. The stock was sold at an average price of $28.01, for a total value of $2,153,408.80.
• On Tuesday, October 21st, Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma stock. The stock was sold at an average price of $28.11, for a total value of $703,508.97.
• On Monday, October 20th, Ra Capital Management, L.P. sold 92,023 shares of Vor Biopharma stock. The stock was sold at an average price of $29.67, for a total value of $2,730,322.41.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The stock was sold at an average price of $29.39, for a total value of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The stock was sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Price Performance

NASDAQ VOR opened at $25.50 on Thursday. The stock has a 50-day moving average of $34.51. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80. The company has a market capitalization of $174.68 million, a P/E ratio of -0.09 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

VOR has been the topic of several recent analyst reports. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Robert W. Baird raised Vor Biopharma from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $20.00 to $64.00 in a research note on Wednesday, October 15th. Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, September 24th. Zacks Research downgraded Vor Biopharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of “Hold” and a consensus price target of $76.50.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. Money Concepts Capital Corp grew its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after buying an additional 26,535 shares in the last quarter. XTX Topco Ltd purchased a new position in Vor Biopharma during the 2nd quarter valued at approximately $66,000. Goldman Sachs Group Inc. grew its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. Ariose Capital Management Ltd purchased a new position in Vor Biopharma during the 3rd quarter valued at approximately $5,368,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Vor Biopharma during the 1st quarter valued at approximately $100,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.